Introduction
Dr. Goldsmith’s clinical and research interests are in high risk and recurrent solid tumors, specifically the pediatric solid tumor neuroblastoma. Her laboratory research expertise is in apoptosis deregulation in cancer, the Bcl-2 family, and novel immunotherapies for neuroblastoma. Her translational research provided the concept behind a first in pediatrics Phase I trial of simvastatin in combination with chemotherapy for recurrent solid/CNS tumors of childhood and helped support the Abbvie first in pediatrics trial of the Bcl-2 inhibitor Venetoclax. She is co-chair of a NANT Precision Medicine Study for recurrent neuroblastoma and the NANT Phase 1 study of the ALK inhibitor Lorlatinib for patients with ALK driven recurrent or refractory neuroblastoma. She also is co-chair of a Phase 2 study in the Children’ Oncology Group (COG) for patients with refractory neuroblastoma. Dr. Goldsmith rounds out her bench to bedside efforts as the Clinical Director of our Refractory and Recurrent Neuroblastoma Program and Aflac Precision Medicine Programs where she and her team work to match a relapsed patient with the appropriate targeted therapy for their recurrent disease.
Focus of Practice
- Neuroblastoma, high risk and relapsed/refractory disease
- Developmental Therapeutics and early phase clinical trials for pediatric solid tumors
- Aflac Precision Medicine Program, Clinical Director - Tumor genetic sequencing to personalize therapy decision making for high risk pediatric cancers
Areas of Interest
- Translational Laboratory research in Recurrent/Refractory Neuroblastoma
- Clinical Research in Neuroblastoma, both locally and through COG and NANT
- Novel Immunotherapy approaches in pediatric solid tumors